Adamax
Adamantyl-Semax · N-Acetyl-Semax-Adamantane analog · Adamantane-modified acetyl hexapeptide
Last updated
At a glance
Overview
What Adamax Is and Why It's Used#
Adamax is a next-generation Semax analog — the familiar ACTH(4-7) hexapeptide backbone fused with the adamantyl moiety borrowed from the P21/P021 neurotrophic scaffold. The modification exists for one reason: the parent Semax molecule clears plasma in minutes and relies on intranasal delivery to reach the CNS at all. Bolt an adamantane group onto the structure and lipophilicity climbs, enzymatic resistance climbs, and blood–brain-barrier penetration climbs with it. The result is a longer-acting, more potent Semax variant that rewards once-daily dosing instead of the 3–5x nasal spray ritual.
The appeal to the nootropics and looksmaxxing community is straightforward: BDNF and NGF upregulation, TrkB sensitization, melanocortin-axis modulation tied to dopaminergic tone, and a documented pro-neurogenic signal in the dentate gyrus from the adamantyl-peptide parent compounds. In practice, subjects running it report sharper verbal recall, lifted drive, reduced mental fatigue, and a subtle mood-stabilizing effect that stacks cleanly with Selank, Cerebrolysin, or a broader longevity protocol. This is not Modafinil-tier acute stimulation — it is a chronic-dosing neurotrophic that builds over 4–8 weeks.
"Peptides incorporating adamantane showed improved penetration into the brain, increased neurogenesis, upregulation of BDNF, and substantial improvements in learning and memory in mouse models." — Li et al., FEBS Letters (2010)
The sections below cover documented Adamax dosage ranges, the SubQ-versus-intranasal route decision, the standard 4–6 week titration schedule, common stacks (Selank, P21, Cerebrolysin, Dihexa), side-effect profile, and the protocol mistakes — late-day dosing, skipping titration, running past 16 weeks without a washout — that most commonly blunt results.
How Adamax works
Dual-Scaffold Design: Semax Core + Adamantyl Handle#
Adamax is a structural hybrid. The peptide backbone is the acetylated ACTH(4-7) analog Semax (Ac-Met-Glu-His-Phe-Pro-Gly-Pro), grafted onto the adamantyl moiety borrowed from Kal Iqbal's P21/P021 neurogenic peptide series. The Semax core carries the melanocortin and neurotrophin-axis activity; the adamantane cage is a lipophilicity handle that extends plasma stability and drives the molecule across the blood-brain barrier.
"Adamantane conjugation increases molecular lipophilicity and is a proven strategy for facilitating CNS penetration and enhancing drug stability against enzymatic degradation." — Wanka L, Iqbal K, Schreiner PR. Chemical Reviews, 2013
The practical consequence: where parent Semax clears plasma in minutes and relies on nose-to-brain transport to produce meaningful CNS exposure, the adamantyl modification gives Adamax a functional window long enough to support once-daily subcutaneous dosing — which is the core reason experienced Semax users migrate to it.
BDNF / TrkB Upregulation in the Hippocampus#
The dominant cognitive mechanism is transcriptional upregulation of brain-derived neurotrophic factor (BDNF) and its high-affinity receptor TrkB, concentrated in the hippocampus and frontal cortex. This is the best-characterized arm of the parent Semax molecule, and there is no mechanistic reason to expect the adamantyl variant to lose it.
"Semax administration led to a pronounced upregulation of BDNF and trkB mRNA expression in the rat hippocampus, indicating activation of neurotrophic pathways relevant for cognition." — Dolotov OV et al. Brain Research, 2006
Downstream, elevated BDNF/TrkB signalling drives CREB phosphorylation, synaptic protein synthesis, and long-term potentiation — the molecular substrate of memory consolidation. This is the mechanism users feel as sharper verbal recall, easier task-switching, and faster learning curves on new material 2–4 weeks into a protocol.
Adamantyl-Driven Neurogenesis#
The adamantane group is not just a PK trick — it carries its own neurogenic signal, inherited from the P21/P021 lineage that pioneered the scaffold. Peptides built on this framework drive dentate-gyrus neurogenesis in the adult hippocampus and restore synaptic plasticity in aged and injured brains.
"Peptides incorporating adamantane showed improved penetration into the brain, increased neurogenesis, upregulation of BDNF, and substantial improvements in learning and memory in mouse models." — Li B, Wanka L, Blanchard J, Liu F, Chohan MO, Iqbal K, Grundke-Iqbal I. FEBS Letters, 2010
"Chronic administration of neurogenic peptides resulted in significant recovery of cognition and increased hippocampal neurogenesis in aged mice, supporting the relevance of the adamantyl-peptide scaffold." — Bolognin S, Buffelli M, Puoliväli J, Iqbal K. Neurobiology of Aging, 2014
This is why Adamax rewards chronic dosing rather than acute testing. Neurogenesis is a weeks-to-months process — new granule cells need to mature, migrate, and integrate. Subjects running 8–12 week blocks report continued accrual of effect through the cycle, consistent with a neurogenic rather than purely neurotransmitter-based mechanism.
Melanocortin Receptor Modulation and Dopaminergic Tone#
The Semax scaffold is an ACTH(4-7) fragment and retains affinity for melanocortin receptors (MC3R/MC4R), which sit upstream of dopaminergic and serotonergic circuits in the ventral tegmental area and nucleus accumbens. This is the presumptive mechanism behind the subjective drive, motivation, and mild mood lift reported on protocol.
"Modulation of the melanocortin receptors (MC3R/MC4R) has been linked to enhanced dopaminergic signaling and represents a plausible mechanism for the antidepressant and cognitive-enhancing profile observed in Semax analogs." — Markov DD, Dolotov OV, Grivennikov IA. Int J Mol Sci, 2023
Two practical implications follow. First, the dopaminergic arm explains why late-afternoon dosing wrecks sleep — the compound's activating profile overlaps with the evening wind-down phase. Morning administration resolves this. Second, the melanocortin activity means Adamax shares a pharmacological family tree with MT-II. The pigmentation signal is far weaker, but subjects with dysplastic nevi or melanoma history should treat MC-axis stimulation as a category-level contraindication rather than a compound-level one.
Neuroprotection and Anti-Apoptotic Signalling#
The combined BDNF/TrkB + adamantyl-neurogenic profile produces a neuroprotective signature in rodent ischemia, hypoxia, and neurodegeneration models. BDNF activates PI3K/Akt survival pathways, suppresses pro-apoptotic Bax/caspase cascades, and buffers glutamatergic excitotoxicity. The adamantyl scaffold adds CNTF-like trophic support on top of this. For physique-focused users, the relevant use-case is not treating disease — it is the post-stressor recovery niche: subjects running the peptide in 4–6 week blocks after concussion, heavy stimulant cycles, sleep-debt periods, or as a biannual neurological maintenance protocol alongside Cerebrolysin or Dihexa.
The mechanistic picture is consistent: Adamax is a slow-building, chronic-dosing neurotrophic with a mild dopaminergic top-note. It does not behave like modafinil or a racetam acutely — the payoff compounds over weeks, which is why the titration schedule and 8-on/8-off cycle structure are non-negotiable parts of running it well.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 200–300 mcg | Once daily | Documented entry-level range |
| Mid | 500–750 mcg | Once daily | Most commonly studied range |
| High | 750–1000 mcg | Once daily | Morning dosing is standard — administration after ~2 PM is the most common cause of sleep disruption in community logs. Titrate upward over 4–6 weeks rather than opening at the advanced dose. |
Cycle length & outcomes
Documented cycle
4–16 weeks
Plateau after
12 wks
Cycle Structure#
Adamax is a chronic-dosing nootropic, not an acute stimulant. The neurotrophic signalling that drives its effects — BDNF/TrkB upregulation, melanocortin-axis modulation, pro-neurogenic activity in the dentate gyrus — builds over weeks, not hours. Protocols reflect this: titrate in, run a defined block, then step off.
| Goal | Cycle Length | Daily Dose | Route |
|---|---|---|---|
| First exposure / tolerance check | 4 weeks | 200–300mcg | SubQ or intranasal |
| Cognitive/focus block | 8–12 weeks | 500–750mcg | SubQ preferred |
| Neuroprotective/longevity layering | 8 weeks (2×/year) | 300–500mcg | SubQ |
| Post-stressor or heavy cognitive load | 4–6 weeks | 750–1000mcg | SubQ or intranasal |
| Mood/motivation block | 6–8 weeks | 500mcg | Intranasal (faster subjective onset) |
Titration Schedule#
Opening at 1mg produces the most common "I don't like this compound" report in community logs — over-stimulation, blunted affect, irritability in week one. The standard upward ramp avoids this:
- Weeks 1–2: 300mcg/day
- Weeks 3–4: 500mcg/day
- Weeks 5–6: 750mcg/day
- Weeks 7+: 1000mcg/day (only if the 750mcg tier is sub-threshold)
Most experienced users settle in the 500–750mcg band and never find a reason to push higher. The dose–response curve is logarithmic — doubling the dose does not double the effect, and the top of the range tends to flatten emotional range rather than sharpen cognition.
Onset & Time Course#
- Subjective onset: 30–60 minutes post-dose, peaking around 60–90 minutes.
- Functional duration: ~20 hours, supporting once-daily dosing despite the short plasma half-life of the parent Semax scaffold.
- Full effect window: neurotrophic endpoints (verbal recall, drive, sustained focus) accumulate over 2–4 weeks. The rodent BDNF/TrkB data from Dolotov and colleagues shows gene-expression changes within hours, but the clinically relevant synaptic remodelling is a multi-week process.
"Semax administration led to a pronounced upregulation of BDNF and trkB mRNA expression in the rat hippocampus, indicating activation of neurotrophic pathways relevant for cognition." — Dolotov OV et al., Brain Research (2006)
"Chronic administration of neurogenic peptides resulted in significant recovery of cognition and increased hippocampal neurogenesis in aged mice, supporting the relevance of the adamantyl-peptide scaffold." — Bolognin S et al., Neurobiology of Aging (2014)
Timing Within the Day#
Morning dosing is non-negotiable for most users. Administration after ~2 PM is the single most common cause of sleep disruption in community logs — the compound is subtle enough that users underestimate its stimulatory tail, then lose an hour of sleep onset that night. If a split is preferred (intranasal users often do this), both doses land before early afternoon.
On/Off-Cycle Structure#
No published tolerance data exists for Adamax specifically, but receptor-sensitivity dynamics inferred from Semax and from the broader TrkB literature justify the community-standard off-cycle:
- 8 on / 8 off — most common, fits the cognitive-block use case.
- 12 on / 8 off — used by longevity stackers running Adamax alongside Cerebrolysin or Dihexa courses.
- 16 weeks is the outer edge of documented continuous use. Beyond that is uncharted — the off-cycle is what keeps the compound working at the same dose six months later.
Users who skip the off-cycle and report "it stopped working at week 10–14" are the clearest argument for respecting the break.
Bloodwork & Monitoring#
Adamax does not perturb lipids, liver enzymes, haematology, or endocrine axes in any documented way. No routine bloodwork cadence is required, and nothing in the mechanism predicts one. Monitoring is subjective:
- Sleep onset and quality (the earliest warning sign of too-late dosing or too-high dose)
- Mood range — blunted affect is the signal to drop 250mcg
- Verbal recall and sustained focus — the endpoints the compound is actually being run for
- HRV trends for users already tracking
Tapering#
No taper is needed at cycle end. Adamax produces no withdrawal syndrome, no rebound depression, no HPA perturbation on discontinuation. The subjective "coming-off" period is a gradual return to baseline over 1–2 weeks as BDNF expression normalises — not a crash, just a fade. Stacking Selank (300mcg/day intranasal) through the off-cycle is a common bridge for users who want to preserve mood continuity without pushing TrkB signalling further.
Risks & mistakes
Common (most users)#
- Headache — most frequent in week 1, usually mild and frontal. Mitigation: hydrate aggressively, pair the dose with electrolytes, and hold the tier rather than climbing until it resolves.
- Mild over-stimulation / jitteriness — typical when the protocol opens above 500 µg. The fix is titration: open at 200–300 µg for 7–14 days before stepping up.
- Insomnia or fragmented sleep — the single most common subjective complaint, almost always a timing issue. Morning dosing (pre-09:00) resolves it in the majority of logs; anything after ~14:00 is where the pattern shows up.
- Transient irritability or emotional flatness in the first 1–2 weeks — usually settles as melanocortin/BDNF signalling normalises. If it persists past week 3, the dose is too high.
- Injection-site erythema (SubQ) — minor redness or a pinprick welt. Site rotation across abdomen/flank quadrants is standard; no nodule formation reported at typical doses.
- Local nasal irritation / rhinorrhoea (intranasal) — preserved saline vehicle reduces incidence vs plain bac water. Splitting the daily dose across 2–3 sprays rather than a single large volume per nostril helps.
Uncommon (dose-dependent or individual)#
- Blunted affect / reduced emotional range at 1 mg and above — described as "flat" or "robotic" drive. Back the dose down to the 500–750 µg range; the literature on Semax analogs suggests a logarithmic dose–response curve where the top of the ladder offers diminishing returns anyway.
- Epistaxis with aggressive intranasal dosing — usually mechanical irritation from repeated sprays into the same nostril. Alternate nostrils, reduce spray volume, or switch to the SubQ route.
- Anxiety or restlessness in susceptible individuals — more likely in subjects already running stimulants (modafinil, high-dose caffeine, amphetamines). A Selank co-administration (300 µg/day intranasal) is the community-standard offset.
- Appetite shifts — usually mild suppression, occasionally the reverse. Mechanistically plausible via MC3/MC4R tone (Markov et al., 2023); not dose-limiting in most logs.
- Loss of effect past week 10–14 — not a side effect per se, but the most common reason for dose creep. The correct response is to run the off-cycle, not to escalate.
No routine bloodwork is required for Adamax specifically — it does not perturb lipids, liver enzymes, endocrine axes, or haematology in any documented way. Subjective logs (mood, cognition, sleep, HRV) are the monitoring surface.
Rare but serious#
- Seizure-threshold events — no documented cases in Semax or P21 literature, but melanocortin and BDNF/TrkB modulators have mechanistically mixed seizure-threshold signals. Any new focal neurological symptom, aura, or unexplained syncope is a stop-immediately signal.
- Severe allergic / hypersensitivity reaction — rare with peptides of this class but possible. Facial swelling, urticaria, or bronchospasm warrants immediate discontinuation and standard emergency care.
- Persistent mood disturbance (dysphoria, anhedonia lasting beyond discontinuation) — reported anecdotally at very high chronic doses. Discontinue and run a full 8-week washout.
- Pigmented lesion change — given the shared melanocortin-axis engagement with MT-II-class peptides, any new or changing mole during a cycle warrants dermatological review and immediate cessation.
Hard contraindications#
- Active or recently treated CNS malignancy. BDNF, CNTF, and TrkB upregulation (Dolotov et al., 2006; Li et al., 2010; Bolognin et al., 2014) is the mechanism of benefit and also the reason this line does not get crossed.
- Pregnancy or pregnancy potential. No reproductive toxicology exists for Adamax or the adamantyl-peptide scaffold.
- Seizure disorder. Mixed mechanistic signals on seizure threshold with BDNF/melanocortin modulators — the risk is not quantified and the compound is not worth the gamble.
- Personal or family history of melanoma or dysplastic nevi. The melanocortin-axis overlap with MT-II-class peptides is mild but real; stacking Adamax on top of any existing pigmented-lesion risk profile is not justifiable.
- Known peptide hypersensitivity.
Gender and cycle considerations#
Adamax is non-hormonal. There is no aromatase activity, no HPTA suppression, no androgen-receptor binding, and no virilization risk. Dosing is bodyweight-independent and applies uniformly across male and female research subjects. No PCT is required and Adamax does not interact with AAS, SARM, or peptide-hormone cycles run in parallel — it is cycle-compatible with effectively anything in the physique/looksmaxxing toolkit. The one universal constraint is the off-cycle: 8-on / 8-off or 12-on / 8-off is the community-standard structure, driven by the assumption that tonic TrkB engagement downregulates receptor sensitivity over time. The off-cycle is not optional.
FAQ — Adamax
Where to buy
Real Peptides
Affiliate link — we may earn a commission at no cost to you.
- Adamax Peptide 10mgBuy Adamax
Research & citations
5 studies cited on this page.
Conclusion
Adamax is a next-gen neurotrophic peptide, designed for users seeking durable cognitive enhancement and neuroprotection beyond standard Semax. Its adamantyl modification yields potent BBB penetration and sustained BDNF elevation, ideal for looksmaxxing, productivity, and recovery-focused research setups.
Key takeaways:
- Typical daily dose: 300–750 µg (subcutaneous or intranasal), titrated upward over 4–6 weeks
- Once-daily morning dosing is standard; late-day use commonly disrupts sleep
- Cycle length: 8–12 weeks on, with equal-length off-cycle to maintain efficacy
- Stacks cleanly with Selank (for mood/anxiolysis), Cerebrolysin (for deeper neuroprotection), and Dihexa or P21 analogs
- Headline benefits: upregulated BDNF, improved focus, sharper verbal recall, and neurogenic support as validated in preclinical models
- Side effects: mild and transient at recommended doses; overstimulation is most common with aggressive titration
For cognitive performance, mood resilience, or long-term brain health protocols, Adamax stands out as a sophisticated and high-value upgrade in the Semax-based nootropics category.